Recent Updates
Recently added Catalysts

PF-07275315

Phase 2

Atopic Dermatitis | Small molecule | Dermatology |Pfizer, Inc.|Last Updated: May 4, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindCONTROLLEDDMC
Total Trials1
Total Enrollment340
FDA Designations
No designations recorded
Clinical trial landscape

PF-07275315 · 4 trials · 4 indications

Phase 2 2Phase 1 2
NCT06977581A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaAsthma
RECRUITING252 Analytics
NCT05995964A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisAtopic Dermatitis
RECRUITING340 Analytics
PHASE2RECRUITING
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
NCT06977581252
Unlock trial analytics
PHASE2RECRUITING
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
NCT05995964340
Unlock trial analytics
Study Endpoints
Primary Endpoints
Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Week 12

FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.

Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and AEs/SAEs leading to treatment discontinuation
Baseline through Week 24

Incidence of treatment-emergent AEs, treatment-emergent SAEs, and treatment-emergent AEs/SAEs leading to treatment discontinuation

Clinically significant, treatment-related laboratory abnormalities
Baseline through Week 24

Incidence of clinically significant changes in laboratory tests

Clinically significant, treatment-related abnormalities in vital signs
Baseline through Week 24

Incidence of clinically significant changes in vital signs

Clinically significant, treatment-related electrocardiogram (ECG) abnormalities
Baseline through Week 24

Incidence of clinically significant changes in ECG

The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.
Week 16

EASI75 (≥75% improvement from baseline) at Week 16

Maximum Observed Plasma Concentration (Cmax)
Up to Day 181
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Up to Day 181
area under the concentration-time curve from time 0 to 336 hours (AUC336)
Up to Day 181
Area under the concentration-time curve from time 0 to infinity (AUCinf)
Up to Day 181
Area under the concentration-time curve from 0 to time of last measurable concentration (AUClast)
Up to Day 181
Terminal phase half-life (t½)
Up to Day 181
Incidence of treatment-emergent adverse events (TEAEs)
Up to Day 181
Incidence of treatment-emergent serious adverse events (SAEs)
Up to Day 181
Incidence of abnormal and clinically relevant changes in vital signs
Up to Day 181
Incidence of abnormal and clinically relevant changes in electrocardiogram
Up to Day 181
Incidence of abnormal and clinically relevant changes in laboratory assessments
Up to Day 181
Number of participants with Adverse Events (AEs)
Baseline through study completion, approximately 561 days

Incidence and severity of AEs

Number of participants with clinically meaningful change from baseline in laboratory Tests Results
Baseline through study completion, approximately 561 days

Number of Participants With Change From Baseline in Laboratory Tests Results

Number of participants with clinically meaningful change from baseline in vital signs
Baseline through study completion, approximately 561 days

Number of participants with change from baseline in vital signs

Number of participants with Serious AEs (SAEs)
Baseline through study completion, approximately 561 days

Incidence and severity of SAEs

Number of participants with clinically meaningful change from baseline in ECG parameters
Baseline through study completion, approximately 561 days

number of participants with change from baseline in ECG parameters

Secondary Endpoints
Change from baseline in pre-bronchodilator Percent (%) Predicted FEV1 at Week 12
Week 12
Change from baseline in pre-bronchodilator FEV1 at all time points
Baseline through Week 24
Change from baseline in pre-bronchodilator % Predicted FEV1 at all time points
Baseline through Week 24
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Treatment Arm AEXPERIMENTALPF-07275315
Treatment Arm BEXPERIMENTALPF-07275315
Treatment Arm CEXPERIMENTALPF-07275315
Treatment Arm DPLACEBO_COMPARATORPlacebo
Stage 1_PF-07275315EXPERIMENTALStage 1 PF-07275315 Injections over 12 weeks
Stage 1_PF-07264660EXPERIMENTALStage 1 PF-07264660 Injections over 12 weeks
Stage 1_PlaceboEXPERIMENTALStage 1 Placebo Injections over 12 weeks
Stage 2_PF-07275315 _Dose AEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose BEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose CEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose DEXPERIMENTALStage 2 PF-07275315 or PF-07264660 Injections over 12 weeks.
Stage 2_PlaceboEXPERIMENTALStage 2 Placebo Injections over 12 weeks.
Stage 3_Placebo+PF-07275315_Dose AEXPERIMENTALStage 3 Placebo Injections for 16 weeks followed by PF-07275315 Injections for 16 weeks.
Stage 3_PF-07275315_Dose BEXPERIMENTALStage 3 PF-07275315 Injections for 32 weeks.
Stage 4_PF-07264660_Dose AEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PF-07264660_Dose BEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PF-07264660_Dose CEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PlaceboEXPERIMENTALStage 2 Placebo Injections for 12 weeks
PF-07275315EXPERIMENTALParticipants will receive a single dose of PF-07275315 via IV infusion
PlaceboPLACEBO_COMPARATORParticipants will receive a single dose of placebo via IV infusion
ActiveEXPERIMENTALPF-07275315
Interventions
NameTypeDescription
PF-07275315DRUGsubcutaneous injection
PlaceboOTHERsubcutaneous injection
PF-07264660DRUGsubcutaneous injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites132

Inclusion Criteria: Must meet the following asthma criteria: 1. History of persistent, moderate-to-severe asthma for at least 12 months prior to screening. 2. Must have experienced at least 1 asthma exacerbation requiring treatment with systemic steroids (oral or parenteral) for 3 days or more wit...

Countries:United StatesArgentinaBelgiumBulgariaChinaCzechiaHungaryItalyJapanPolandSouth AfricaSouth KoreaSpainTaiwanUnited KingdomAustraliaCanadaGermany
Unlock Eligibility Criteria
Competitive Landscape -Atopic Dermatitis 80 trials

Top 20 of 26 competitors

CompanyTickerTrialsLead PhaseDrugs
Eli Lilly and CompanyLLY6PHASE3Baricitinib, corticosteroid
AbbVie, Inc.ABBV10PHASE3Upadacitinib, corticosteroids
Pfizer Inc.PFE12PHASE3Abrocitinib
Sanofi SA Sponsored ADRSNY13PHASE3Amlitelimab
Regeneron Pharmaceuticals, Inc.REGN4PHASE3Dupilumab
Incyte CorporationINCY3PHASE3Ruxolitinib, Vehicle
Organon & Co.OGN1PHASE3Tapinarof , 1%, Vehicle
Apogee Therapeutics, Inc.APGE3PHASE2APG777
Novartis AG Sponsored ADRNVS2PHASE2GIA632
Kymera Therapeutics, Inc.KYMR1PHASE2KT-621
Corvus Pharmaceuticals, Inc.CRVS1PHASE2Soquelitinib
Johnson & JohnsonJNJ1PHASE2JNJ-95597528
Nektar TherapeuticsNKTR1PHASE2Rezpegaldesleukin
Celldex Therapeutics, Inc.CLDX1PHASE2Barzolvolimab
Evommune, Inc.EVMN1PHASE2EVO756
Aclaris Therapeutics, Inc.ACRS1PHASE2ATI-045
Q32 Bio IncQTTB1PHASE2ADX-914
Turn Therapeutics Inc.TTRX1PHASE2GX-03
Sunshine Biopharma IncorporatedSBFM2PHASE3611, corticosteroid
Co-Diagnostics, Inc.CODX1PHASE3611
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT05995964primaryCompletionDate: changed
LOWMay 26, 2026NCT06977581primaryCompletionDate: changed
LOWMay 24, 2026NCT05995964studyFirstPostDate: changed
LOWMay 24, 2026NCT06977581studyFirstPostDate: changed